Prospective Validation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder

Journal of Urology

Volumn 183, Issue 1, 2010, Pages 62-67

  Schlomer, Bruce J ^a   Ho, Richard ^a   Sagalowsky, Arthur ^a   Ashfaq, Raheela ^a   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

carcinoma; cytology; fluorescence; in situ hybridization; transitional cell; urinary bladder; urothelium

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER PATIENT; CANCER RISK; CANCER STAGING; CYSTOSCOPY; FALSE NEGATIVE RESULT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POPULATION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 71249154354     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.08.157     Document Type: Article

References (19)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71
2. Daniltchenko D.I., Riedl C.R., Sachs M.D., et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174 (2005) 2129
3. Denzinger S., Burger M., Walter B., et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69 (2007) 675
4. Svatek R.S., Lee D., and Lotan Y. Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?. Urology 66 (2005) 65
5. Hedelin H., Holmang S., and Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 36 (2002) 344
6. Paez A., Coba J.M., Murillo N., et al. Reliability of the routine cytological diagnosis in bladder cancer. Eur Urol 35 (1999) 228
7. Raitanen M.P., Aine R., Rintala E., et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 41 (2002) 284
8. Nabi G., Greene D.R., and O'Donnell M. How important is urinary cytology in the diagnosis of urological malignancies?. Eur Urol 43 (2003) 632
9. Lotan Y., and Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61 (2003) 109
10. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66 (2005) 35
11. Sarosdy M.F., Schellhammer P., Bokinsky G., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 (2002) 1950
12. Sarosdy M.F., Kahn P.R., Ziffer M.D., et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176 (2006) 44
13. Lotan Y., Bensalah K., Ruddell T., et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 179 (2008) 2164
14. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303
15. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810
16. Skacel M., Fahmy M., Brainard J.A., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 (2003) 2101
17. Raitanen M.P., Aine R., Kylmala T., et al. The dilemma of suspicious urine cytology in patients being followed for bladder cancer. Ann Chir Gynaecol 90 (2001) 256
18. Ferra S., Denley R., Herr H., et al. Reflex UroVysion testing in suspicious urine cytology cases. Cancer Cytopathol 117 (2009) 7
19. Yoder B.J., Skacel M., Hedgepeth R., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 127 (2007) 295